[SCHEDULE 13G/A] Lexeo Therapeutics, Inc. SEC Filing
Janus Henderson Group plc disclosed a significant passive position in Lexeo Therapeutics, reporting beneficial ownership of 3,684,383 shares, representing 11.1% of the company's common stock. The filing shows shared voting and dispositive power over these shares rather than sole control, and the filer certifies the holdings are held in the ordinary course of business and not to change or influence control.
Separately, Janus Henderson Biotech Innovation Master Fund Ltd is reported to beneficially own 2,041,481 shares (about 6.2%) with shared voting and dispositive power. The filing includes a power of attorney authorizing Janus Henderson personnel to make required regulatory filings on behalf of the group.
Janus Henderson Group plc ha reso nota una rilevante posizione passiva in Lexeo Therapeutics, dichiarando la titolarit脿 effettiva di 3.684.383 azioni, pari al 11,1% del capitale ordinario della societ脿. La comunicazione precisa che sulle azioni sussiste una potest脿 di voto e dispositiva condivisa, non il controllo esclusivo, e il dichiarante attesta che le partecipazioni sono detenute nell'ordinario esercizio dell'attivit脿 e non con l'intento di modificare o influenzare il controllo.
Separatamente, Janus Henderson Biotech Innovation Master Fund Ltd risulta essere titolare effettivo di 2.041.481 azioni (circa il 6,2%) con analoga potest脿 di voto e dispositiva condivisa. La comunicazione include inoltre una procura che autorizza il personale di Janus Henderson a presentare le necessarie comunicazioni regolamentari per conto del gruppo.
Janus Henderson Group plc declar贸 una posici贸n pasiva significativa en Lexeo Therapeutics, informando la propiedad beneficiaria de 3.684.383 acciones, que representan el 11,1% del capital social ordinario. La presentaci贸n se帽ala que existe poder de voto y dispositvo compartido sobre dichas acciones en lugar de control exclusivo, y el declarante certifica que las participaciones se mantienen en el curso ordinario de negocios y no con la finalidad de cambiar o influir en el control.
Por separado, Janus Henderson Biotech Innovation Master Fund Ltd figura como titular beneficiario de 2.041.481 acciones (aproximadamente el 6,2%) con poder de voto y dispositivo compartido. La presentaci贸n incluye adem谩s un poder que autoriza al personal de Janus Henderson a realizar las presentaciones reglamentarias requeridas en nombre del grupo.
Janus Henderson Group plc電� Lexeo Therapeutics鞐� 雽�頃� 欷戩殧頃� 靾橂彊鞝� 歆�攵勳潉 瓿奠嫓頃橂┌, 須岇偓 氤错喌欤� 欷� 3,684,383欤�毳� 鞁れ 氤挫湢頃橁碃 鞛堨柎 鞝勳泊鞚� 11.1%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 氍胳劀鞐愲姅 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 韱奠牅臧� 鞎勲媹霛� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 鞛堨潓鞚� 氇呾嫓頃橁碃 鞛堨溂氅�, 氤挫湢 氍茧焿鞚� 鞓侅梾鞚� 韱奠儊鞝� 氩旍渼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 欤茧牑電� 氇╈爜鞚� 鞎勲嫎鞚� 鞁犼碃鞚胳澊 歃濍獏頃橁碃 鞛堨姷雼堧嫟.
氤勲弰搿�, Janus Henderson Biotech Innovation Master Fund Ltd電� 鞎� 6.2%鞐� 頃措嫻頃橂姅 2,041,481欤�毳� 鞁れ 氤挫湢頃� 瓴冹溂搿� 氤搓碃霅橃棃鞙茧┌ 毵堨艾臧�歆�搿� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖 氍胳劀鞐愲姅 攴鸽９鞚� 雽�鞁犿暣 頃勳殧頃� 攴滌牅 鞁犼碃毳� 頃� 靾� 鞛堧弰搿� Janus Henderson 歆侅洂霌れ棎瓴� 鞙勳瀯鞛レ潉 攵�鞐暅 雮挫毄霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Janus Henderson Group plc a d茅clar茅 une position passive significative dans Lexeo Therapeutics, signalant la propri茅t茅 b茅n茅ficiaire de 3 684 383 actions, repr茅sentant 11,1% du capital social ordinaire. Le d茅p么t indique qu'il existe un pouvoir de vote et de disposition partag茅 sur ces actions plut么t qu'un contr么le exclusif, et le d茅clarant certifie que les d茅tentions sont maintenues dans le cours normal des affaires et n'ont pas pour but de modifier ou d'influencer le contr么le.
厂茅辫补谤茅尘别苍迟, Janus Henderson Biotech Innovation Master Fund Ltd d茅tiendrait effectivement 2 041 481 actions (environ 6,2%) avec un m锚me pouvoir de vote et de disposition partag茅. Le dossier comprend 茅galement une procuration autorisant le personnel de Janus Henderson 脿 effectuer les d茅clarations r茅glementaires requises au nom du groupe.
Janus Henderson Group plc hat eine bedeutende passive Beteiligung an Lexeo Therapeutics gemeldet und gibt den wirtschaftlichen Besitz von 3.684.383 Aktien an, was 11,1% des Stammkapitals entspricht. Die Meldung weist darauf hin, dass 眉ber diese Aktien gemeinsame Stimm- und Verf眉gungsbefugnisse bestehen und kein alleiniger Kontrollanspruch vorliegt; der Meldende best盲tigt, dass die Best盲nde im gew枚hnlichen Gesch盲ftsverkehr gehalten werden und nicht dazu dienen, die Kontrolle zu 盲ndern oder zu beeinflussen.
Separat wird angegeben, dass Janus Henderson Biotech Innovation Master Fund Ltd wirtschaftlich 2.041.481 Aktien (etwa 6,2%) h盲lt, ebenfalls mit gemeinsamer Stimm- und Verf眉gungsbefugnis. Die Meldung enth盲lt zudem eine Vollmacht, die Janus Henderson-Mitarbeiter zur Abgabe der erforderlichen regulatorischen Meldungen im Namen der Gruppe erm盲chtigt.
- Material institutional ownership disclosed: Janus Henderson Group reports 3,684,383 shares (11.1%) beneficial ownership, signaling credible investor interest.
- Affiliated fund holds >5%: Janus Henderson Biotech Innovation Master Fund Ltd holds 2,041,481 shares (6.2%), indicating multiple related entities have meaningful stakes.
- None.
Insights
TL;DR: Institutional investor disclosed a material, passive >10% stake; no stated intent to influence control.
The Schedule 13G filing documents that Janus Henderson Group plc holds 3,684,383 shares (11.1%) of LXEO with shared voting and dispositive power, while an affiliated fund holds 2,041,481 shares (6.2%). Because the filing is a 13G and includes a certification that the position is held in the ordinary course of business, the holder characterizes the stake as passive rather than activist. For investors, the disclosure signals meaningful institutional ownership that may increase monitoring and engagement, but it does not, on its face, indicate an intent to change company control.
TL;DR: Material ownership disclosed with shared powers; governance influence appears limited per filing language.
The report shows shared voting and dispositive authority rather than sole control, and the filer explicitly states the securities are not held to influence control. The inclusion of a power of attorney for filings is routine for large asset managers and confirms delegated filing authority. From a governance standpoint, this is a material disclosure of institutional ownership but does not by itself signal a change in board-level dynamics or control intentions.
Janus Henderson Group plc ha reso nota una rilevante posizione passiva in Lexeo Therapeutics, dichiarando la titolarit脿 effettiva di 3.684.383 azioni, pari al 11,1% del capitale ordinario della societ脿. La comunicazione precisa che sulle azioni sussiste una potest脿 di voto e dispositiva condivisa, non il controllo esclusivo, e il dichiarante attesta che le partecipazioni sono detenute nell'ordinario esercizio dell'attivit脿 e non con l'intento di modificare o influenzare il controllo.
Separatamente, Janus Henderson Biotech Innovation Master Fund Ltd risulta essere titolare effettivo di 2.041.481 azioni (circa il 6,2%) con analoga potest脿 di voto e dispositiva condivisa. La comunicazione include inoltre una procura che autorizza il personale di Janus Henderson a presentare le necessarie comunicazioni regolamentari per conto del gruppo.
Janus Henderson Group plc declar贸 una posici贸n pasiva significativa en Lexeo Therapeutics, informando la propiedad beneficiaria de 3.684.383 acciones, que representan el 11,1% del capital social ordinario. La presentaci贸n se帽ala que existe poder de voto y dispositvo compartido sobre dichas acciones en lugar de control exclusivo, y el declarante certifica que las participaciones se mantienen en el curso ordinario de negocios y no con la finalidad de cambiar o influir en el control.
Por separado, Janus Henderson Biotech Innovation Master Fund Ltd figura como titular beneficiario de 2.041.481 acciones (aproximadamente el 6,2%) con poder de voto y dispositivo compartido. La presentaci贸n incluye adem谩s un poder que autoriza al personal de Janus Henderson a realizar las presentaciones reglamentarias requeridas en nombre del grupo.
Janus Henderson Group plc電� Lexeo Therapeutics鞐� 雽�頃� 欷戩殧頃� 靾橂彊鞝� 歆�攵勳潉 瓿奠嫓頃橂┌, 須岇偓 氤错喌欤� 欷� 3,684,383欤�毳� 鞁れ 氤挫湢頃橁碃 鞛堨柎 鞝勳泊鞚� 11.1%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 氍胳劀鞐愲姅 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 韱奠牅臧� 鞎勲媹霛� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 鞛堨潓鞚� 氇呾嫓頃橁碃 鞛堨溂氅�, 氤挫湢 氍茧焿鞚� 鞓侅梾鞚� 韱奠儊鞝� 氩旍渼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 欤茧牑電� 氇╈爜鞚� 鞎勲嫎鞚� 鞁犼碃鞚胳澊 歃濍獏頃橁碃 鞛堨姷雼堧嫟.
氤勲弰搿�, Janus Henderson Biotech Innovation Master Fund Ltd電� 鞎� 6.2%鞐� 頃措嫻頃橂姅 2,041,481欤�毳� 鞁れ 氤挫湢頃� 瓴冹溂搿� 氤搓碃霅橃棃鞙茧┌ 毵堨艾臧�歆�搿� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖 氍胳劀鞐愲姅 攴鸽９鞚� 雽�鞁犿暣 頃勳殧頃� 攴滌牅 鞁犼碃毳� 頃� 靾� 鞛堧弰搿� Janus Henderson 歆侅洂霌れ棎瓴� 鞙勳瀯鞛レ潉 攵�鞐暅 雮挫毄霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Janus Henderson Group plc a d茅clar茅 une position passive significative dans Lexeo Therapeutics, signalant la propri茅t茅 b茅n茅ficiaire de 3 684 383 actions, repr茅sentant 11,1% du capital social ordinaire. Le d茅p么t indique qu'il existe un pouvoir de vote et de disposition partag茅 sur ces actions plut么t qu'un contr么le exclusif, et le d茅clarant certifie que les d茅tentions sont maintenues dans le cours normal des affaires et n'ont pas pour but de modifier ou d'influencer le contr么le.
厂茅辫补谤茅尘别苍迟, Janus Henderson Biotech Innovation Master Fund Ltd d茅tiendrait effectivement 2 041 481 actions (environ 6,2%) avec un m锚me pouvoir de vote et de disposition partag茅. Le dossier comprend 茅galement une procuration autorisant le personnel de Janus Henderson 脿 effectuer les d茅clarations r茅glementaires requises au nom du groupe.
Janus Henderson Group plc hat eine bedeutende passive Beteiligung an Lexeo Therapeutics gemeldet und gibt den wirtschaftlichen Besitz von 3.684.383 Aktien an, was 11,1% des Stammkapitals entspricht. Die Meldung weist darauf hin, dass 眉ber diese Aktien gemeinsame Stimm- und Verf眉gungsbefugnisse bestehen und kein alleiniger Kontrollanspruch vorliegt; der Meldende best盲tigt, dass die Best盲nde im gew枚hnlichen Gesch盲ftsverkehr gehalten werden und nicht dazu dienen, die Kontrolle zu 盲ndern oder zu beeinflussen.
Separat wird angegeben, dass Janus Henderson Biotech Innovation Master Fund Ltd wirtschaftlich 2.041.481 Aktien (etwa 6,2%) h盲lt, ebenfalls mit gemeinsamer Stimm- und Verf眉gungsbefugnis. Die Meldung enth盲lt zudem eine Vollmacht, die Janus Henderson-Mitarbeiter zur Abgabe der erforderlichen regulatorischen Meldungen im Namen der Gruppe erm盲chtigt.
FAQ
How many LXEO shares does Janus Henderson Group plc report owning?
What percent of LXEO does Janus Henderson Group plc own?
Does the filing indicate Janus Henderson intends to influence control of Lexeo (LXEO)?
What stake does Janus Henderson Biotech Innovation Master Fund Ltd report in LXEO?
What voting and dispositive power is reported?
